Edit
Grey Wolf Therapeutics
https://www.gwt.bio/Last activity: 27.01.2023
Active - Reference to Grey Wolf Therapeutics Stage
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals.
Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology.
Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.
For more information, visit the website or email enquiries@gwt.bio.
Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology.
Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.
For more information, visit the website or email enquiries@gwt.bio.
Founded date: 2017
Investors 1
| Date | Name | Website |
| 27.01.2023 | Earlybird ... | earlybird.... |
Mentions in press and media 2
| Date | Title | Description |
| 28.03.2023 | Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours | First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Gr... |
| 27.01.2023 | British Patient Capital invests $7m in immuno-oncology specialist Grey Wolf Therapeutics | 26 January 2023: British Patient Capital has participated in the $49m Series B funding round of immuno-oncology specialist Grey Wolf Therapeutics as the company looks to begin testing their novel small molecule anti-cancer treatment in the ... |